Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Bain Capital Moves to Acquire Majority Stake in Echo Marketing 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
BRISBANE, Calif., March 09, 2017 -- KaloBios Pharmaceuticals, Inc. (OTC:KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, announced that Cameron Durrant, MD, chairman and CEO, will present a company overview at the 29th Annual ROTH Conference.
The ROTH conference will be held March 12-15, 2017, at The Ritz-Carlton, Laguna Niguel, in Dana Point, Calif.
For more information on the conference, please visit www.roth.com/main/Page.aspx?PageID=7280.
About KaloBios Pharmaceuticals, Inc.
KaloBios Pharmaceuticals, Inc. (OTC:KBIO) is an emerging biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases through innovative and responsible business models. Lead compounds in the KaloBios portfolio are benznidazole for the potential treatment of Chagas disease in the U.S., and the proprietary monoclonal antibodies, lenzilumab and ifabotuzumab (formerly KB004), for the potential treatment of various solid and hematologic cancers such as CMML and potentially JMML. For more information, visit www.kalobios.com.
CONTACT: Investors: Mike Cole O: 949-259-4988 C: 949-444-1341 [email protected] Media: Lisa Guiterman O: 301-217-9353 C: 202-330-3431 [email protected]
